Pharmaceutical research and exhibi...

Pharmaceutical research and exhibition costs are growing faster than the market. (1) This stretch is important, because pharmaceutical companies finance R&D from a relatively fixed percentage (10%-20%) of global incomes As revenues stabilize and costlinesss increase, the industry thus finds itself in a cash press closely (2) Given the current economic environment, it is unlikely that incomes will increase to keep pace with unmanaged increases in evolution costs. For this reason, expenses must be contained or the industry will face unwanted program and personnel cutbacks.

Factors